68Ga-DOTATOC

Download PDF Česká verzia

Authors: Michal Budinský; Petr Vyšinský; Stanislav Synek; Beatrix Bencsiková; Iveta Selingerová; Zdeněk Řehák
Published in the journal: Čes. slov. Farm., 2021; 70, 136-141
Category: Původní práce
doi: https://doi.org/https://doi.org/10.5817/CSF2021-4-136

Summary

The radiopharmaceutical ⁶⁸Ga-DOTATOC represents the latest radiopharmaceutical in the diagnosis of a neuroendocrine tumor with somatostatin receptor overexpression. Technological and economic difficulties of preparing and quality control of the radiopharmaceutical limit its use to specialised departments. Background of the department with rich experience with radiopharmaceuticals for positron emission tomography allows handling more difficult ⁶⁸Ga-radiopharmacy and may increase and improve the care of oncology patients.

Keywords:

68Ga-DOTATOC – radiopharmacy – neuroendocrine tumors

Zdroje

1. Patel Y. C. Somatostatin and its receptor family. Frontiers in Neuroendocrinology 1999; 20(3), 157–198.

2. Patel Y. C., Strikant C. B. Somatostatin receptors. Trends Endocrinol Metab. 1997; 8(10), 398–405.

3. Papotti M., Bongiovanni M., Volante M., Allia E., Landolfi S., Helboe L., Schindler M., Cole S. L., Bussolati G. Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors: a correlative immunohistochemical and reverse- transcriptase polymerase chain reaction analysis. Virchows arch. 2002; 440(5), 461–175.

4. Vítek P. Neuroendokrinní nádory, in Onkologie v klinické praxi. Standardní přístupy v diagnostice a léčbě vybraných zhoubných nádorů. Praha: Mladá fronta 2019.

5. Sedláčková E., Bajčiová V., a kol. Epidemiologie NEN ve světe a v ČR, registry. In: Neuroendokrinní nádory. Praha: Maxdorf 2016.

6. Wang L., Tang K., Zhang Q., Li H., Wen Z., Zhang H. Somatostatin Receptor-Based MoleculaImaging and Therapy for Neuroendocrine Tumors. Biomed Res Int. 2013; 2013, 102819.

7. Pauwels E., Cleeren F., Bormans G., Deroose C. M. Somatostatin receptor PET ligands – the next generation for clinical practice. Am. J. Nucl. Med. Mol. Imag. 2018; 8(5), 311–331.

8. Gabriel M., Decristoforo C., Kendler D., Dobrozemsky G., Heute D., Uprimny C., Kovacs P., Guggenberg E., Bale R., Virgolini I. J. 68Ga-DOTA-Tyr3-Octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J. Nucl. Med. 2007; 48, 508–518.

9. Bencsiková B., Řehák Z., Budinský M., Hejnová R., Kozáková Š., Kiss I., Demlova R., Svoboda M. 68Ga- DOTA-TOC PET/CT vyšetření u pacienta s gastroenteropankreatickým neuroendokrinním nádorem – první vyšetření v České republice. Klin. Onkol. 2019; 32(5), 390–392.

10. Monaharan P., Lamarca A., Navalkissoor S., Calero J., Chan P. S, Julyan P., Sierra M., Caplin M., Valle J. Safety, tolerability and clinical implementation of „ready-to-use“ 68gallium-DOTA0-Tyr3-octreotide (68Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastropancreatic neuroendocrine tumors (GEP-NETs). ESMO Open. 2020; 5, e000650.

11. Calero J. Kits or synthesis modules? A review of both strategies. Ga-68 for beginners. London: UKRG 2018.

12. Murby B. Radiation risk assessment. Ga-68 for beginners. London: UKRG 2018.